Highlights Brii Biosciences Limited

Equities

2137

KYG1645A1094

Delayed Hong Kong S.E. Other stock markets 03:42:42 2024-05-14 EDT			5-day change	1st Jan Change
1.23 ^HKD	0.00%		-3.91%	-46.05%

03-25	Transcript : Brii Biosciences Limited, 2023 Earnings Call, Mar 25, 2024
03-22	Brii Biosciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Brii Biosciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-22	CI
PBrii Biosciences Limited Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting 2023	11-13	CI
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating Brii-179 (Vbi-2601) in Combination with Peg-Ifn for the Treatment of Chronic Hepatitis B	23-09-06	CI
Brii Biosciences Limited Announces Data from Interim Analysis of A Randomized, Placebo-Controlled and Double-Blinded Phase 2 Study of Brii-179	23-09-06	CI
Brii Biosciences Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-22	CI
Shionogi Inc. completed the acquisition of Qpex Biopharma, Inc. from Brii Biosciences Limited and Others.	23-07-30	CI
VBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership To Address Both Prevention and Treatment in License and Collaboration Agreements for up to $437 Million Plus Royalties	23-07-05	CI
Brii Biosciences to Acquire Development, Commercialization Rights on Bacterial Drug in Greater China; Shares Up 4%	23-06-26	MT
Shionogi Inc. entered into a definitive agreement to acquire Qpex Biopharma, Inc. from Brii Biosciences Limited and Others for $140 million.	23-06-25	CI
Brii Biosciences Limited Announces Dosing of First Subject in Phase 1 Clinical Trial Evaluating BRII-297	23-05-31	CI
Brii Biosciences' Loss Narrows Down in 2022	23-03-24	MT
Brii Biosciences Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-24	CI
Brii Biosciences Limited Announces Interim Findings from A Phase 2 Study	23-02-14	CI
Brii Biosciences Limited Provides Update on Strategic Clinical Development Progress	22-12-27	CI
Brii Biosciences Announces New Data from Two Phase 1 Studies	22-10-19	CI
Brii Biosciences Limited Announces Topline Results from a Phase 1 Study Evaluating its Long-Acting, Single-Injection Therapy, BRII-296, in the Development for the Treatment of Postpartum Depression	22-09-26	CI
Brii Biosciences' H1 Loss Narrows on Absence of Fair Value Losses	22-08-23	MT
Brii Biosciences Limited Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-23	CI
Brii Bio Says COVID-19 Therapy Effective Against Omicron Subvariants; Shares Rise 3%	22-07-26	MT
Brii Biosciences Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Live Omicron Virus BA.4/5 and BA.2.12.1 Subvariants	22-07-26	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Brii Biosciences Limited

Equities

2137

KYG1645A1094

Highlights

Filters